Health and bio names delivered a steady session of clinical and regulatory progress rather than dramatic surprises. Sareum Holdings advanced on a key toxicology milestone for its psoriasis candidate, Advanced Medical Solutions Group posted revenue growth despite order delays, and GSK moved closer to a label expansion for its meningitis B vaccine.
Sareum clears toxicology hurdle for psoriasis drug
Sareum Holdings (LON:SAR) completed dosing in a toxicology programme supporting its psoriasis drug candidate, a step the company says is critical to assembling the full Phase 2-enabling regulatory package. Chief Scientific Officer Dr John Reader called it an important milestone that builds on encouraging Phase 1 results, with Dr Stephen Parker also involved in the programme. Shares in Sareum rose 4.167% to 25.0p on the update.
AMS grows revenue as order delays weigh on timing
Advanced Medical Solutions Group (LON:AMS) reported rising revenue even as some customer orders were pushed back, with chief executive Chris Meredith pointing to a strengthened portfolio and a pipeline of significant opportunities as grounds for confidence in sustained long-term value creation. The shares edged up 0.54% to 280.5p following the update.
GSK advances Bexsero booster label expansion
GSK (LON:GSK) saw the European Medicines Agency accept its filing for a label update to Bexsero, its meningitis B vaccine, which would allow a single booster dose for those aged 10 and over who were previously vaccinated. The regulator will now review the proposed update. GSK shares slipped 0.37% to 1909.5p.
